Prime Medicine (PRME) Share-based Compensation (2021 - 2026)
Prime Medicine's (PRME) quarterly Share-based Compensation came in at $4.6 million in Q1 2026, down 18.25% YoY from $5.7 million in Q1 2025, and up 108.52% on a QoQ basis from -$54.5 million in Q4 2025.
Prime Medicine (PRME) Share-based Compensation (2021 - 2026) Analysis & Trends
Prime Medicine (PRME) has 6 years of Share-based Compensation data on file, last reported at $4.6 million in Q1 2026.
- Quarterly Share-based Compensation fell 18.25% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (up 396.94% YoY) and the FY2025 annual result came in at $29.3 million, down 34.87% from the prior year.
- Share-based Compensation grew to $4.6 million in Q1 2026, from -$54.5 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $78.1 million in Q2 2025 to a low of -$54.5 million in Q4 2025.
- A 5-year average of $7.9 million and a median of $5.0 million in 2023 frame the typical range for Share-based Compensation.
- The widest YoY moves for Share-based Compensation: up 650.18% in 2024, down 700.97% in 2024.
- Tracing PRME's Share-based Compensation over 5 years: stood at $24.7 million in 2022, then slumped by 125.16% to -$6.2 million in 2023, then surged by 608.93% to $31.6 million in 2024, then sank by 272.24% to -$54.5 million in 2025, then surged by 108.52% to $4.6 million in 2026.
- The last three Share-based Compensation figures came in at $4.6 million (Q1 2026), -$54.5 million (Q4 2025), and $78.1 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Prime Medicine | 558.48 Mn | 558.48 Mn | - | 4.87 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.87 Mn |
| Jun 30, 2026 | 4.87 Mn |
| Mar 31, 2026 | 4.64 Mn |
| Mar 31, 2026 | 4.64 Mn |
| Dec 31, 2025 | -54.49 Mn |
| Dec 31, 2025 | -54.49 Mn |
| Jun 30, 2025 | 78.08 Mn |
| Jun 30, 2025 | 78.08 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Mar 31, 2025 | 5.68 Mn |
| Sep 30, 2024 | 31.64 Mn |
| Sep 30, 2024 | 31.64 Mn |
| Jun 30, 2024 | -31.64 Mn |
| Jun 30, 2024 | -31.64 Mn |
| Mar 31, 2024 | 44.94 Mn |
| Mar 31, 2024 | 44.94 Mn |
| Dec 31, 2023 | -6.22 Mn |
| Dec 31, 2023 | -6.22 Mn |
| Sep 30, 2023 | 4.22 Mn |
| Sep 30, 2023 | 4.22 Mn |